insights_auto
Why is DEVA down 2.47%?
Dive Deeperchevron_right
DEVA:IST
Deva Holding AS
TRY 80.95
arrow_downward
-2.47%(-2.05) 1D
Oct 13, 6:10:00 PM GMT+3 · TRY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DEVA...
Open
TRY 82.65
High
TRY 83.25
Low
TRY 80.15
Mkt. cap
16.19B
Avg. vol.
653.35K
Volume
306.70K
52-wk high
TRY 109.30
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Open
TRY 82.65
High
TRY 83.25
Low
TRY 80.15
Mkt. cap
16.19B
Avg. vol.
653.35K
Volume
306.70K
52-wk high
TRY 109.30
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
News stories
From web sources and news partners
Traders Union
·
1 hour ago
Ryan Detrick: S&P 500 up about 18% since March 30 2026 after midterm year pattern
TradingView
·
1 hour ago
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
HDFC Sky
·
58 minutes ago
US Stocks End Mixed as Chip Selloff Hits Nasdaq
巴士的報
·
2 hours ago
U.S. stocks end lower amid chip selloff
Profile
DEVA Holding A.Ş. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements.
A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas.
As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS